Early decreases in KRAS mutant allele frequency (MAF) predicts clinical benefit to the PLK1 inhibitor onvansertib in combination with FOLFIRI/bev in 2L treatment of metastatic colorectal carcinoma (mCRC)

Category Primary study
JournalAnnals of Oncology
Year 2022
This article has no abstract
Epistemonikos ID: c43b417125e0b3ff1c7d3f7c1d939447bce09909
First added on: Feb 15, 2025